Insulin market in Iran
Insulin market in Iran
Abstract
Background: The Iranian pharmaceutical market is substantial, comprising a mix of domestically produced and imported medications. Among these, insulin plays a critical role in the treatment of diabetic patients. This study aims to examine insulin from both import and domestic production perspectives within the Iranian pharmaceutical market during the year 2023. Methods: The research is a descriptive analytical study that investigates the insulin market using statistical data from the Food and Drug Administration of Iran. Results: The findings indicate that a significant portion of the insulin available in Iran's pharmaceutical market is sourced through imports from European countries. Conclusion: Given the importance of this medication for diabetes management and the current conditions in the country, it is essential for drug policies to shift towards increasing domestic production of insulin. The government should remove barriers faced by local manufacturers to enable them to meet the majority of the country's insulin needs effectively.Ozougwu, J., et al., The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol, 2013. 4(4): p. 46-57. https://doi.org/10.5897/jpap2013.0001
Association, A.D., Diagnosis and classification of diabetes mellitus. Diabetes care, 2014. 37(Supplement_1): p. S81-S90.https://doi.org/10.2337/dc14-s081
Mukhtar, Y., A. Galalain, and U. Yunusa, A modern overview on diabetes mellitus: a chronic endocrine disorder. European Journal of Biology, 2020. 5(2): p. 1-14.https://doi.org/10.47672/ejb.409
Salsali, A. and M. Nathan, A review of types 1 and 2 diabetes mellitus and their treatment with insulin. American journal of therapeutics, 2006. 13(4): p. 349-361.https://doi.org/10.1097/00045391-200607000-00012.
Khalilov, R. and S. Abdullayeva, MECHANISMS OF INSULIN ACTION AND INSULIN RESISTANCE. Advances in Biology & Earth Sciences, 2023. 8(2).
Li, M., et al., Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal transduction and targeted therapy, 2022. 7(1): p. 216. https://doi.org/10.1038/s41392-022-01073-0
Tiwari, P., Recent trends in therapeutic approaches for diabetes management: a comprehensive update. Journal of diabetes research, 2015. 2015(1): p. 340838. https://doi.org/10.1155/2015/340838
Boscari, F. and A. Avogaro, Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives. Reviews in Endocrine and Metabolic Disorders, 2021. 22(2): p. 217-240. https://doi.org/10.1007/s11154-021-09635-3
Jansson, P.A., Endothelial dysfunction in insulin resistance and type 2 diabetes. Journal of internal medicine, 2007. 262(2): p. 173-183. https://doi.org/10.1111/j.1365-2796.2007.01830.x
Banday, M.Z., A.S. Sameer, and S. Nissar, Pathophysiology of diabetes: An overview. Avicenna journal of medicine, 2020. 10(04): p. 174-188. https://doi.org/10.4103/ajm.ajm_53_20
Powers, A.C. and D. D’Alessio, Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. Goodman and Gilman’s The Pharmacological Basis of Therapeutics 12th edition. Edited by Brunton LL, Chabner BA, Knollman BC. New York: McGraw Hill Publishers, 2011: p. 1237-1274.
Zhao, X., et al., The crucial role and mechanism of insulin resistance in metabolic disease. Frontiers in endocrinology, 2023. 14: p. 1149239.
Esteghamati, A., et al., Diabetes in Iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Scientific reports, 2017. 7(1): p. 13461. https://doi.org/10.1038/s41598-017-13379-z
Jafarvand, E., A. Ataey, and S. Edalati, Epidemiology and death trends due to diabetes in Iran. Internal Medicine Today, 2021. 27(2): p. 198-213.
Shahraz, S., et al., Prevalence of diabetes and prediabetes, and achievements in diabetes control in Iran; the results of the STEPS of 2016. Archives of Iranian medicine, 2022. 25(9): p. 591. https://doi.org/10.34172/aim.2022.94
Mirzaei, M., et al., Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from Yazd health study. BMC public health, 2020. 20(1): p. 166. https://doi.org/10.1186/s12889-020-8267-y
Noshad, S., et al., Diabetes care in Iran: where we stand and where we are headed. Annals of global health, 2015. 81(6): p. 839-850. https://doi.org/10.1016/j.aogh.2015.10.003
Esteghamati, A., et al., The economic costs of diabetes: a population-based study in Tehran, Iran. Diabetologia, 2009. 52: p. 1520-1527. https://doi.org/10.1007/s00125-009-1398-4
Haghdoost, A., et al., Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. EMHJ-Eastern Mediterranean Health Journal, 15 (3), 591-599, 2009, 2009. https://doi.org/10.26719/2009.15.3.591
Javanbakht, M., et al., Projection of diabetes population size and associated economic burden through 2030 in Iran: evidence from micro-simulation Markov model and Bayesian meta-analysis. PloS one, 2015. 10(7): p. e0132505. https://doi.org/10.1371/journal.pone.0132505
Sussman, M., et al., Estimated lifetime economic burden of type 1 diabetes. Diabetes technology & therapeutics, 2020. 22(2): p. 121-130. https://doi.org/10.1089/dia.2019.0398
Tao, B.T. and D.G. Taylor, Economics of type 1 diabetes. Endocrinology and metabolism clinics of north america, 2010. 39(3): p. 499. https://doi.org/10.1016/j.ecl.2010.05.004
Lopez-Bastida, J., et al., Social economic costs of type 1 diabetes mellitus in pediatric patients in Spain: CHRYSTAL observational study. Diabetes research and clinical practice, 2017. 127: p. 59-69. https://doi.org/10.1016/j.diabres.2017.02.033
Stedman, M., et al., Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation. BMJ open, 2020. 10(5): p. e033231. https://doi.org/10.1136/bmjopen-2019-033231
Tao, B., et al., Estimating the cost of type 1 diabetes in the US: a propensity score matching method. PloS one, 2010. 5(7): p. e11501. https://doi.org/10.1371/journal.pone.0011501
Gardner, D.W., et al., Type 1 Diabetes Mellitus, in Comprehensive Management of High Risk Cardiovascular Patients. 2016, CRC Press. p. 173-212. https://doi.org/10.3109/9781420019667-11
Jendle, J., et al., Achieving good glycemic control early after onset of diabetes: a cost-effectiveness analysis in patients with type 1 diabetes in Sweden. Diabetes Therapy, 2018. 9: p. 87-99. https://doi.org/10.1007/s13300-017-0344-6
Lithovius, R., Utilization and costs of prescription medication in patients with type 1 diabetes.
Ramesh, S., Diabetes Increases Health Care Costs in the United States: How Focusing on Self-Management & the Patient-Physician Relationship Will Curb Costs. Annals Advance Directive, 2019. 29: p. 191.
Parker, E.D., et al., Economic costs of diabetes in the US in 2022. Diabetes Care, 2024. 47(1): p. 26-43.
| Files | ||
| Issue | Vol 10 No 4 (2024) | |
| Section | Original Article(s) | |
| Keywords | ||
| Import Domestic production Insulin market | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
